{
    "clinical_study": {
        "@rank": "85595", 
        "arm_group": [
            {
                "arm_group_label": "0.06% Resiquimod Gel - A", 
                "arm_group_type": "Experimental", 
                "description": "60 mg gel\nOnce daily prior to normal sleeping hours\n5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
            }, 
            {
                "arm_group_label": "0.06% Resiquimod Gel - B", 
                "arm_group_type": "Experimental", 
                "description": "100 mg gel\nOnce daily prior to normal sleeping hours\n5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
            }, 
            {
                "arm_group_label": "0.06% Resiquimod Gel - C", 
                "arm_group_type": "Experimental", 
                "description": "100 mg gel\nOnce daily prior to normal sleeping hours\n5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation\nThe BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is the observation and description of the preliminary efficacy of\n      resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of\n      patients."
        }, 
        "brief_title": "Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nodular Basal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Basal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed consent form.\n\n          -  Male or non-pregnant, non-lactating female, \u2265 18 years.\n\n          -  Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk\n             or arms.\n\n          -  nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth.\n\n          -  Willing and able to participate in the trial as an outpatient and comply with all\n             trial requirements.\n\n        Exclusion Criteria:\n\n          -  nBCC located close to or at mouth or eyes.\n\n          -  Patients who have had an organ transplant.\n\n          -  Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV),\n             known thyroid abnormalities, known depression.\n\n          -  An open wound or an infection in treatment area.\n\n          -  Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the\n             treatment or surrounding area that might impair trial assessments.\n\n          -  Evidence of an active infection or systemic cancer.\n\n          -  Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle\n             pain, chills) within a week before start of the trial.\n\n          -  Known allergy or hypersensitivity to any of the trial gel ingredients.\n\n          -  Evidence of unstable or uncontrolled clinically significant medical conditions as\n             determined by the investigator (e.g., renal or hepatic disease).\n\n          -  Current alcohol abuse or chemical dependency as assessed by the investigator.\n\n          -  Patient who is detained or committed to an institution by a law court or by legal\n             authorities.\n\n          -  Participation in another clinical trial within one month before start of the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808950", 
            "org_study_id": "SP848-nBCC-1104"
        }, 
        "intervention": [
            {
                "arm_group_label": "0.06% Resiquimod Gel - A", 
                "intervention_name": "0.06% Resiquimod Gel - A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.06% Resiquimod Gel - B", 
                "intervention_name": "0.06% Resiquimod Gel - B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.06% Resiquimod Gel - C", 
                "intervention_name": "0.06% Resiquimod Gel - C", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Hauttumorcentrum Charit\u00e9 (HTCC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland"
                    }, 
                    "name": "Universitaetsspital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Switzerland: Ethikkommission", 
                "Switzerland: Swissmedic", 
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Histological cure rate", 
            "safety_issue": "No", 
            "time_frame": "8 weeks after a maximal treatment period of 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Global judgment of efficacy (by investigator) by means of a 7-point scale", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after a maximal treatment period of 4 weeks"
            }, 
            {
                "description": "local skin reactions as erythema, edema, erosion/ulceration, exudate, dryness, encrustation judged by investigator by means of 5-point scales (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).", 
                "measure": "Evaluation of local tolerability by means of 5-point scales", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "measure": "Evaluation of systemic tolerability based on haematology and blood chemistry values and vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "measure": "Global judgment of tolerability by investigator by means of a 6-point scale", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks after a maximal treatment period of 4 weeks"
            }
        ], 
        "source": "Spirig Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spirig Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}